Deal of the Month: $70 million raised to advance the non-vaccine approach by Leyden Labs

Leyden Labs is a biotech company based in Amsterdam, the Netherlands, and was founded in 2020. The company focuses on developing innovative solutions to protect people from respiratory viruses such as influenza and coronaviruses. Leyden Labs uses a Mucosal Protection Platform that administers broadly protective antibodies through the nose. This approach offers a new way to prevent infections without giving people a shot. Leyden Labs' goal is to stop infections early to prevent the spread of viruses.

Kennedy Van der Laan acted as legal advisors to lead investors ClavystBio and Polaris Partners in the $70 million financing round of Leyden Labs. The deal team was led by Jan-Berend Möller, Lukas Suijkerbuijk and Maurits Wismeijer with multidisciplinary support from our experts in Labor Law, Privacy and Health Law, among others. Together with RPC, who served as legal advisors in Singapore, they also guided the strategic acquisition of CoV Biotechnology, successfully completing both the financing and the acquisition.

Leyden Labs has raised $70 million to further develop their intranasal antibody programs. This means they are developing medicine that can be used through the nose to protect people from viruses such as influenza and coronaviruses. The funding round included several investors, including ClavystBio and Polaris Partners, and already existing investors, including GV (Google Ventures) and Casdin Capital, and will be used to continue their research and development. This technology offers a new way to protect people without having to get a vaccine, which is a great benefit.